Plasma and buffy coat concentration of 8-methoxypsoralen in patients treated with extracorporeal photopheresis.


Recently, a new therapy involving an extracorporal activation of orally administered 8-methoxypsoralen (8-MOP), photosensitizing furocoumarin, is established for the treatment of different skin diseases, extracorporeal photopheresis (ECP). The pharmacokinetic profile of 8-MOP has been pursued as part of a clinical study which should assess the efficacy of… (More)


  • Presentations referencing similar topics